---
title: "Jazz Pharmaceuticals (JAZZ) news: offering, merger and buyback"
url: "https://aibio.space/companies/jazz-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "JAZZ offering, merger and buyback news. Jazz Pharmaceuticals news for investors: Jazz Pharmaceuticals sells medicines for sleep disorders, epilepsy and…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Jazz has an approval in hand and a bigger balance sheet to carry

Jazz is a profitable rare-disease company that has just widened its oncology and epilepsy bets, funded partly with new debt. The Ziihera approval is the main event of the year, and the launch will show whether it pays off. Concentration in two products and a larger debt load are the points to track.

Read the full desk view

aibio.space Investor Rank · Opinion

**8** /10 Positive view

Profitable with a first-line Ziihera approval in hand, but Xywav and Epidiolex are about 63% of revenue and new debt has raised leverage.

- **Technology**: 2/2

- **Odds**: 2/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Validated and diversified.** Jazz sells approved sleep, epilepsy and oncology products, and Ziihera has a Phase 3 survival result behind its first-line gastroesophageal label.

- **Odds**: **Mostly commercial risk.** The approved products carry data and labels, while ABS-1230 and the Modeyso Phase 3 trial still face the usual late and early stage attrition.

- **Balance sheet**: **Cash generative but leveraged.** $2.2 billion in cash and $4.4 billion of debt principal at June 30, before an $820 million acquisition and a $1.1 billion note sale.

- **Main risk**: **Revenue concentration.** Xywav and Epidiolex made up about 63% of second-quarter revenue, and the Ziihera launch is only weeks old.

- **Watch next**: **Third-quarter results.** They should show first-line Ziihera uptake, the new cash and debt balances, and the Zepzelca label change.

## Top news on Jazz

1. 2026-09-23 Debt Financing [Jazz Pharmaceuticals extends term loan to 2033, adds $273,310,355.18](https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/) Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier.
2. 2026-08-27 Financings [Jazz prices $1.1 billion of exchangeable notes and repurchases $225 million of shares](https://aibio.space/news/jazz-prices-1-1-billion-exchangeable-notes-repurchases-225-million/) The 1.875% notes due 2032 carry an exchange price of about $355.24, a 42.5% premium to the Aug. 26 close. The offering was upsized from $1.0 billion.
3. 2026-08-26 Debt Financing [Jazz plans $1.0 billion exchangeable notes offering with share buyback](https://aibio.space/news/jazz-plans-1-0-billion-exchangeable-notes-offering-share-buyback/) Jazz Investments I Limited plans to sell $1.0 billion of exchangeable notes due 2032. Jazz also expects to buy back up to $225.0 million of its ordinary shares from note purchasers.
4. 2025-04-21 Mergers [Jazz Pharmaceuticals completes acquisition of Chimerix for about $935 million in cash](https://aibio.space/news/jazz-pharmaceuticals-completes-acquisition-chimerix-about-935-million/) Jazz paid $8.55 per share in cash after its tender offer for Chimerix expired on April 17, 2025. Chimerix is now a wholly owned subsidiary of Jazz.
5. 2025-03-05 Mergers [Jazz Pharmaceuticals agrees to acquire Chimerix for $8.55 per share in cash](https://aibio.space/news/jazz-pharmaceuticals-agrees-acquire-chimerix-8-55-share-cash/) Jazz Pharmaceuticals agreed to buy Chimerix for $8.55 a share in cash, about $935 million in total, through a tender offer. The main asset, dordaviprone, is still awaiting an FDA decision, and Chimerix owes Jazz a $35 million fee in some cases if it accepts a rival offer.

## Dates

**3Q26**
Jazz plans to submit a labeling supplement removing the second-line indication for Zepzelca [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)

**1H27**
Interim overall survival analysis for the Phase 3 ACTION trial of Modeyso [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)

**By June 30, 2027**
Chief commercial officer Samantha Pearce plans to retire by then or when a successor is appointed [Source](https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/jazz-20261006.htm)

**Not dated**
Milestone payments of up to $500 million tied to ABS-1230 approval and sales [Source](https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596dex991.htm)

## The money

$2.2 billion in cash, cash equivalents and investments at June 30, 2026, against $4.4 billion of long-term debt principal and $885 million of undrawn revolver capacity. Since then Jazz paid $820 million upfront for Actio and priced $1.1 billion of exchangeable notes. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)

Total revenues of $1,208.3 million in Q2 2026, up 16% year over year; 2026 guidance $4.60 billion to $4.75 billion. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)

## Risks on the record

- Xywav and Epidiolex together were about 63% of Q2 2026 revenue (calculated from the reported product lines). [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)
- Long-term debt principal of $4.4 billion at June 30, 2026, before the new $1.1 billion exchangeable notes. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)
- Ziihera carries boxed warnings for diarrhea and embryo-fetal toxicity. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Jazz Pharmaceuticals?

8 out of 10, our positive view. Profitable with a first-line Ziihera approval in hand, but Xywav and Epidiolex are about 63% of revenue and new debt has raised leverage. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What did the FDA approve for Jazz Pharmaceuticals in August 2026?

On Aug. 25, 2026 the FDA approved Ziihera (zanidatamab) with tislelizumab and chemotherapy, and with chemotherapy alone in IHC 3+ disease, for first-line HER2-positive gastroesophageal adenocarcinoma. The triplet showed median overall survival of 26.4 months versus 19.2 months for trastuzumab plus chemotherapy. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm)

### How much did Jazz pay for Actio Biosciences?

Jazz agreed to pay $820 million upfront and up to $500 million in approval and sales milestones for Actio, whose lead drug is ABS-1230 for KCNT1-related epilepsy. The deal closed on Sept. 15, 2026. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/exhibit991closingpr.htm)

### What was Jazz Pharmaceuticals' revenue in the second quarter of 2026?

Total revenues were $1,208.3 million, up 16% from a year earlier. Jazz raised its 2026 revenue guidance to $4.60 billion to $4.75 billion. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)

### How much cash and debt does Jazz Pharmaceuticals have?

At June 30, 2026, Jazz held $2.2 billion in cash, cash equivalents and investments and had $4.4 billion of long-term debt principal. In August it priced $1.1 billion of 1.875% exchangeable notes due 2032. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000119312526377073/d127542dex992.htm)

### What are the next Jazz Pharmaceuticals clinical catalysts?

Jazz expects an interim overall survival analysis for the Phase 3 ACTION trial of Modeyso in the first half of 2027. It also plans a Zepzelca label supplement in the third quarter of 2026 and is running registrational zanidatamab trials in breast cancer. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm)

### What is the latest Jazz Pharmaceuticals (JAZZ) stock news?

Our latest story on Jazz Pharmaceuticals, dated Sep 23, 2026: "Jazz Pharmaceuticals extends term loan to 2033, adds $273,310,355.18". Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier. [Source](https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/)

### What is Jazz Pharmaceuticals's latest stock offering or financing news?

Our latest financing story, dated Aug 27, 2026: "Jazz prices $1.1 billion of exchangeable notes and repurchases $225 million of shares". The 1.875% notes due 2032 carry an exchange price of about $355.24, a 42.5% premium to the Aug. 26 close. The offering was upsized from $1.0 billion. [Source](https://aibio.space/news/jazz-prices-1-1-billion-exchangeable-notes-repurchases-225-million/)

### Who were the underwriters or placement agents on Jazz Pharmaceuticals's offering?

From our story: Bank of America, N.A. is administrative agent. [Source](https://aibio.space/news/jazz-prices-1-1-billion-exchangeable-notes-repurchases-225-million/)

### Does Jazz Pharmaceuticals have debt, a term loan or convertible notes?

Our latest debt story, dated Sep 23, 2026: "Jazz Pharmaceuticals extends term loan to 2033, adds $273,310,355.18". Bank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier. [Source](https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/)

### How much cash does Jazz Pharmaceuticals have?

From our story of Aug 27, 2026: At June 30 it held $2.2 billion in cash and investments against $4.4 billion of debt principal. [Source](https://aibio.space/news/jazz-prices-1-1-billion-exchangeable-notes-repurchases-225-million/)

### Is Jazz Pharmaceuticals being acquired or merging?

Our latest merger story, dated Apr 21, 2025: "Jazz Pharmaceuticals completes acquisition of Chimerix for about $935 million in cash". Jazz paid $8.55 per share in cash after its tender offer for Chimerix expired on April 17, 2025. Chimerix is now a wholly owned subsidiary of Jazz. [Source](https://aibio.space/news/jazz-pharmaceuticals-completes-acquisition-chimerix-about-935-million/)

### What is Jazz Pharmaceuticals's market cap?

We do not publish live share prices. In its annual report, Jazz Pharmaceuticals plc put the market value of shares held by non-affiliates (public float) at $6.25 billion as of Jun 30, 2025. Source

### Is Jazz Pharmaceuticals a smaller reporting company?

SEC records list Jazz Pharmaceuticals plc's filer category as: Large accelerated filer. Source

### Where is Jazz Pharmaceuticals headquartered?

SEC records list its business address as FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7. Source

## Legal and investor matters

Checked against Jazz Pharmaceuticals filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Note 10 of the 10-Q filed 2026-08-03 states Jazz believes there is no other litigation pending, beyond the matters it describes there, that could have a material adverse effect on its results of operations or financial condition. It covers that quarterly report only. [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)

1. 2026-09-23 Financing Jazz reprices and extends U.S. dollar term loan to 2033 On September 23, 2026, Jazz Financing Lux S.a r.l., a Luxembourg subsidiary of Jazz Pharmaceuticals plc, signed an amendment to its 2021 credit agreement. The amendment extended the maturity of the outstanding U.S. dollar term loan B-2 and repriced it as Tranche B-3 Dollar Term Loans. The applicable margin fell by 50 basis points, and the remaining balance is payable on May 5, 2033. [Jazz Form 8-K, 2026-09-23](https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm)
2. 2026-08-31 Financing Jazz closes $1.25 billion exchangeable notes and repurchases shares On August 31, 2026, Jazz Investments I Limited, a Bermuda subsidiary of Jazz, closed a private offering of $1.25 billion of 1.875% exchangeable senior notes due 2032, including the full exercise of a $150.0 million option. Net proceeds were estimated at $1,226.4 million. Jazz also repurchased about $225.0 million of its ordinary shares from note purchasers at $249.29 per share, the last reported sale price on August 26, 2026. [Jazz Form 8-K, 2026-08-31](https://www.sec.gov/Archives/edgar/data/1232524/000119312526377073/d127542d8k.htm)
3. 2026-02-20 Litigation Jazz sues Tris Pharma over Xyrem and Xywav patents Jazz filed two patent infringement suits against Tris Pharma on February 20, 2026, in the U.S. District Court for the District of New Jersey. Jazz says Tris filed a Section 505(b)(2) NDA that references Xyrem and Xywav. The 10-Q filed 2026-08-03 states that the court denied Tris's motions to dismiss in July 2026, and Tris then filed answers and counterclaims alleging the patents are invalid and not infringed. U.S. District Court for the District of New Jersey · Status: pending [Jazz Form 10-Q, 2026-08-03](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)
4. 2026-01-23 Litigation New York False Claims Act qui tam suit against Jazz unsealed On January 23, 2026, the U.S. District Court for the Southern District of New York unsealed a qui tam lawsuit against Jazz under the New York state False Claims Act. Jazz's 10-Q says the docket reflects that the New York Attorney General declined to participate, and that the suit repeats almost verbatim allegations by the same whistleblower in a Massachusetts case dismissed in September 2025. The plaintiff amended its complaint in May 2026 and Jazz moved to dismiss it in July 2026. The 10-Q filed 2026-08-03 says the motion remains pending. U.S. District Court for the Southern District of New York · Status: pending [Jazz Form 10-Q, 2026-08-03](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)
5. 2025-10-27 Litigation Court approves Xyrem antitrust class settlement; Jazz resolves all claims The Xyrem antitrust litigation was filed by purported direct and indirect purchasers, who allege Jazz's patent settlements with generic makers violate antitrust and consumer protection laws. It was consolidated in the U.S. District Court for the Northern District of California. Jazz agreed to pay $145.0 million to the indirect purchaser class, and the court approved that settlement on October 27, 2025. Jazz recognized $233.5 million of expense in 2025 for resolving the litigation. U.S. District Court for the Northern District of California · Status: settled [Jazz Form 10-K, 2026-02-24](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm)
6. 2025-10-21 Litigation Jazz and Avadel settle patent, antitrust and trade secret disputes On October 21, 2025, subsidiaries of Jazz and subsidiaries of Avadel Pharmaceuticals plc signed a global settlement of all disputes between them, including Jazz's patent infringement litigation against Avadel in the U.S. District Court for the District of Delaware and Avadel's counterclaims alleging anticompetitive conduct. Jazz denies all alleged wrongdoing. Jazz's 10-K says that as of October 27, 2025 the Delaware court had dismissed all relevant matters with prejudice. Jazz recorded a $90.0 million expense in 2025 for the resolution. U.S. District Court for the District of Delaware · Status: settled [Jazz Form 8-K, 2025-10-22](https://www.sec.gov/Archives/edgar/data/1232524/000119312525245815/d65147d8k.htm)
7. 2025-09-23 Litigation Federal qui tam case over Xyrem dismissed in Massachusetts In July 2022 Jazz received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting Xyrem-related documents. In July 2024 the U.S. District Court for the District of Massachusetts unsealed a qui tam whistleblower lawsuit underlying that subpoena. The docket indicates the United States and a number of states declined to intervene. On September 23, 2025, the court granted Jazz's motion and dismissed the federal claims with prejudice and the state-law claims without prejudice. U.S. District Court for the District of Massachusetts · Status: dismissed [Jazz Form 10-Q, 2026-08-03](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)
8. 2024-08-27 Litigation Xywav patent litigation against Lupin and Teva continues Jazz has sued Lupin and Teva in the U.S. District Court for the District of New Jersey over proposed generic versions of Xywav, in a consolidated case with no trial date set. On August 27, 2024, Jazz filed further suits over a newly issued patent. In March 2026 Jazz settled with Granules, a later filer, which the 10-Q says does not resolve the Lupin and Teva cases. U.S. District Court for the District of New Jersey · Status: pending [Jazz Form 10-Q, 2026-08-03](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Ziihera (zanidatamab-hrii) | First-line HER2-positive gastroesophageal adenocarcinoma; previously treated biliary tract cancer | Approved (GEA Aug 25, 2026); registrational trials in breast cancer [Source](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm) |
| Modeyso (dordaviprone) | H3 K27M-mutant diffuse glioma (Phase 3 ACTION after radiotherapy) | Marketed since Aug 2025; Phase 3 ACTION interim OS expected 1H27 [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) |
| ABS-1230 | KCNT1-related epilepsy | Phase 1b/2a KYRON (registrational design); Fast Track, Orphan [Source](https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596dex991.htm) |
| Epidiolex (cannabidiol) | Seizure disorders; DEE, JME and adult LGS expansion trials | Marketed; Phase 3 and Phase 2/3 trials; capsule NDA submitted [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) |
| Zanidatamab | HER2-positive previously treated colorectal cancer | Breakthrough Therapy designation granted [Source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Jazz's results release is brief on the Zepzelca setback, and its Ziihera survival claims run ahead of the numbers

Jazz's results release cites the Zepzelca LAGOON results as the basis for removing the second-line indication while the 10-Q states the missed primary endpoint, and its financial figures match the 10-Q. The gaps are in the Ziihera messaging, where an Aug. 31 survival claim came without a hazard ratio, and in the Xywav story, where the release leaves out the exclusivity dates and generic suits the filing lists.

1. Science · weight medium Doublet survival win announced without the numbers **The company said:** "The Ziihera plus chemotherapy OS hazard ratio improved compared with the first interim analysis." [source](https://investor.jazzpharma.com/node/23236/pdf) **The record says:** ClinicalTrials.gov lists HERIZON-GEA-01 as randomized but open-label (masking: none), with 920 participants and two primary outcomes: "Progression-free survival (PFS) by BICR" and "Overall survival". The 10-Q, filed before this readout, credits the statistically significant survival benefit only to "The investigational arm containing zanidatamab plus tislelizumab and chemotherapy". [source](https://clinicaltrials.gov/study/NCT05152147) **Our view:** The Aug. 31 release calls the doublet survival result statistically significant and clinically meaningful but gives no hazard ratio, median survival or p-value. Until the data are presented, investors cannot judge how large the gain is for the regimen without tislelizumab.
2. Science · weight low "Longest median OS" is a cross-trial comparison **The company said:** "achieving a median OS of 26.4 months versus 19.2 months, representing a greater than seven-month improvement and the longest median OS reported in a Phase 3 trial in HER2+ advanced GEA." [source](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm) **The record says:** The within-trial result, as the 10-Q states it, is that "The greater than seven-month improvement in median overall survival represents a 28% reduction in the risk of death versus the control arm." The same approval release says the regimen without tislelizumab was approved only for "HER2+ IHC 3+" patients, and that benefits across PD-L1 groups come from prespecified subgroup analyses. [source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) **Our view:** The 28% risk reduction against trastuzumab plus chemotherapy is the randomized evidence. The longest-reported claim compares across trials with different patients and eras, and the PD-L1 point rests on subgroups, which are weaker evidence than the primary analysis.
3. Press release vs filing · weight medium Xywav growth story omits exclusivity dates and generic suits **The company said:** "Continued physician and patient demand for the differentiated benefits of low-sodium Xywav ." [source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) **The record says:** The 10-Q says the business "continues to meaningfully depend on Xywav revenues" and that narcolepsy orphan exclusivity runs "through July 21, 2027, (which was subsequently extended to January 21, 2028, because FDA granted pediatric exclusivity)", with IH exclusivity through Aug. 12, 2028. Patent suits against Lupin and Teva over generic Xywav are "ongoing", and a March 2026 settlement with Granules grants a license to certain Orange Book patents that "could, under certain circumstances, allow Granules to launch its generic version of Xywav prior to the expiration of the licensed patents". [source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) **Our view:** Xywav was $471 million of the quarter, by far the largest product. The release frames it on demand alone, while the filing sets out a dated exclusivity runway and open litigation that decide how long that revenue lasts.
4. Press release vs filing · weight low Zepzelca label removal: the release cites LAGOON results, the 10-Q states the miss **The company said:** "Based on the results from the LAGOON trial of Zepzelca in second-line metastatic SCLC, and in alignment with FDA, in 3Q26, we will submit for FDA's review and subsequent action a labeling supplement to remove the second-line indication." [source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) **The record says:** The 10-Q says LAGOON "did not meet its primary OS endpoint evaluating Zepzelca as monotherapy or in combination with irinotecan compared with investigators' choice of topotecan or irinotecan." [source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) **Our view:** The release puts the label change in the business update rather than the headline. It cites the LAGOON results and the planned removal of the second-line indication but does not say the trial missed its primary endpoint; the 10-Q does. Zepzelca still grew 42% on first-line maintenance use.
5. Legal and disclosure record · weight low No securities litigation disclosed; a state qui tam suit is pending **The record says:** Legal Proceedings in the 10-Q lists patent suits Jazz brought over Xywav, Zepzelca, Defitelio and Tris Pharma's oxybate filing, plus qui tam matters. A July 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts about Xyrem underlay a qui tam whistleblower suit unsealed in July 2024, in which the U.S. and a number of states declined to intervene; on Sept. 23, 2025 the court dismissed the federal claims with prejudice and the state-law claims without prejudice. A suit under the New York state False Claims Act, unsealed Jan. 23, 2026 in the Southern District of New York, "repeats almost verbatim allegations" from the dismissed case; the filing says "The docket reflects that the New York Attorney General declined to participate" and Jazz's motion to dismiss is pending. No securities litigation or enforcement disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) **Our view:** The non-patent matters are qui tam whistleblower cases: the federal one began with a USAO subpoena and was dismissed, and the New York one is pending, with the New York Attorney General declining to participate. The patent cases matter more to investors because they set the timing of generic Xywav and Zepzelca entry.

Documents we compared

- [Jazz Q2 2026 results press release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/a2q26financialpr.htm) 2026-08-03
- [Jazz release: FDA approves Ziihera regimens in first-line HER2+ GEA (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/exhibit991pr.htm) 2026-08-25
- [Jazz release: Ziihera plus chemotherapy second interim OS](https://investor.jazzpharma.com/node/23236/pdf) 2026-08-31
- [Jazz Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) 2026-08-03
- [ClinicalTrials.gov NCT05152147 (HERIZON-GEA-01)](https://clinicaltrials.gov/study/NCT05152147) 2026-10-20

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:JAZZ on TradingView](https://www.tradingview.com/symbols/NASDAQ-JAZZ/).

## SEC filings and registration

- **SEC name**: Jazz Pharmaceuticals plc

- **CIK**: 1232524

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: JAZZ (Nasdaq)

- **State or country of incorporation**: L2

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7

- **Phone**: 353-1-634-7800

- **Shares outstanding**: 64,914,577 as of 2026-07-27 (10-Q filed 2026-08-03)

- **Former names**: JAZZ PHARMACEUTICALS INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/jazz-20261006.htm) filed 2026-10-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm) filed 2026-09-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/jazz-20260915.htm) filed 2026-09-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312526377073/d127542d8k.htm) filed 2026-08-31
- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm) filed 2026-08-25
- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/d151973d8k.htm) filed 2026-08-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596d8k.htm) filed 2026-08-10
- [10-Q](https://www.sec.gov/Archives/edgar/data/1232524/000123252426000045/jazz-20260630.htm) filed 2026-08-03

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001232524), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/jazz-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jazz Pharmaceuticals (JAZZ) news: offering, merger and buyback", 2026-10-31, https://aibio.space/companies/jazz-pharmaceuticals/